Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same author

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report.

European heart journal. Case reports·2026
Same author

Bleeding and thrombotic events during micro-axial flow pump support: A European multicenter cohort study.

Critical care (London, England)·2026
Same author

Beyond the STEMI paradigm: Expanding the scope of microAxial flow pump in cardiogenic shock.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Sex-Related Differences in the Management and Outcomes of Patients Across the Spectrum of Aortic Stenosis.

Journal of the American Heart Association·2026
Same author

Experts' recommendations for the management of adult patients with cardiogenic shock.

Archives of cardiovascular diseases·2026

Related Experiment Video

Updated: Jun 24, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Paclitaxel-eluting balloon: from bench to bed.

Axel De Labriolle1, Rajbabu Pakala, Laurent Bonello

  • 1Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC, USA.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|March 25, 2009
PubMed
Summary

Paclitaxel-eluting balloons offer a promising alternative to drug-eluting stents for preventing restenosis after percutaneous coronary intervention. This review explores their potential in local drug delivery to combat in-stent restenosis.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Area of Science:

  • Cardiovascular Interventions
  • Medical Device Technology
  • Pharmacology

Background:

  • Restenosis remains a significant challenge following percutaneous coronary intervention (PCI), evolving from elastic recoil issues in the balloon era to in-stent restenosis (ISR) with stent implantation.
  • Drug-eluting stents (DES) have improved outcomes but concerns persist regarding stent thrombosis and efficacy in complex cases, necessitating alternative strategies.
  • Neointimal hyperplasia is a key driver of ISR, prompting research into novel therapeutic approaches.

Purpose of the Study:

  • To review the concept and available data on non-stent based local drug delivery systems for managing restenosis.
  • To specifically evaluate the preclinical and clinical evidence supporting the use of paclitaxel-eluting balloons (PEBs) as a strategy against in-stent restenosis.

Main Methods:

  • Comprehensive literature review of preclinical studies investigating the efficacy and safety of PEBs.
  • Analysis of clinical trial data assessing the performance of PEBs in patients undergoing PCI.
  • Exploration of the mechanism of action for local paclitaxel delivery via balloon catheters.

Main Results:

  • Preclinical data demonstrate the potential of PEBs to inhibit neointimal hyperplasia and smooth muscle cell proliferation.
  • Clinical studies suggest that PEBs can effectively reduce restenosis rates, particularly in specific lesion subsets.
  • PEBs provide localized drug delivery, potentially mitigating systemic side effects associated with DES.

Conclusions:

  • Non-stent based local drug delivery, exemplified by paclitaxel-eluting balloons, represents a viable alternative to DES for preventing restenosis.
  • PEBs show promise in addressing the limitations of current DES, offering a targeted approach to managing in-stent restenosis.
  • Further research and clinical validation are warranted to establish the optimal role of PEBs in interventional cardiology.